These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27917405)

  • 1. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
    Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
    Kohli A; Osinusi A; Sims Z; Nelson A; Meissner EG; Barrett LL; Bon D; Marti MM; Silk R; Kotb C; Gross C; Jolley TA; Sidharthan S; Petersen T; Townsend K; Egerson D; Kapoor R; Spurlin E; Sneller M; Proschan M; Herrmann E; Kwan R; Teferi G; Talwani R; Diaz G; Kleiner DE; Wood BJ; Chavez J; Abbott S; Symonds WT; Subramanian GM; Pang PS; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
    Lancet; 2015 Mar; 385(9973):1107-13. PubMed ID: 25591505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
    J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
    Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
    Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
    Kawakami Y; Ochi H; Hayes CN; Imamura M; Tsuge M; Nakahara T; Katamura Y; Kohno H; Kohno H; Tsuji K; Takaki S; Mori N; Honda Y; Arataki K; Takahashi S; Kira S; Tamura T; Masuda K; Nakamura T; Kikkawa M; Chayama K
    J Gastroenterol; 2018 Apr; 53(4):548-556. PubMed ID: 28815329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
    Lee HW; Yoo KY; Won JW; Kim HJ
    Gut Liver; 2017 Sep; 11(5):721-727. PubMed ID: 28874040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    Morio R; Imamura M; Kawakami Y; Morio K; Kobayashi T; Yokoyama S; Kimura Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Nelson Hayes C; Aikata H; Takahashi S; Miki D; Ochi H; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol; 2017 Apr; 52(4):504-511. PubMed ID: 27631593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
    Yakoot M; Abdo AM; Abdel-Rehim S; Helmy S
    EBioMedicine; 2017 Jul; 21():182-187. PubMed ID: 28647541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
    Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
    Kohli A; Kapoor R; Sims Z; Nelson A; Sidharthan S; Lam B; Silk R; Kotb C; Gross C; Teferi G; Sugarman K; Pang PS; Osinusi A; Polis MA; Rustgi V; Masur H; Kottilil S
    Lancet Infect Dis; 2015 Sep; 15(9):1049-1054. PubMed ID: 26187031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
    Dahari H; Canini L; Graw F; Uprichard SL; Araújo ES; Penaranda G; Coquet E; Chiche L; Riso A; Renou C; Bourliere M; Cotler SJ; Halfon P
    J Hepatol; 2016 Jun; 64(6):1232-9. PubMed ID: 26907973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.